Response to Tenofovir Among Lamivudine-experienced Hepatitis B and HIV-coinfected Adolescents
Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. We determined hepatitis B virus (HBV) suppression rates among 18 lamivudine (3TC)-experienced HBV-human immunodeficiency virus-coinfected adolescents after treatment with tenofovir disoproxil fumurate (TDF). At TDF initiation, their m...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| 格式: | 雜誌 |
| 出版: |
2017
|
| 在線閱讀: | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85007247655&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/40623 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|
| 總結: | Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. We determined hepatitis B virus (HBV) suppression rates among 18 lamivudine (3TC)-experienced HBV-human immunodeficiency virus-coinfected adolescents after treatment with tenofovir disoproxil fumurate (TDF). At TDF initiation, their median age was 17.6 years, and duration of 3TC exposure was 7.3 years. Eleven patients (61%) achieved HBV DNA < 60 IU/mL after 48 weeks on TDF and 3TC which was similar to adult studies, although hepatitis B surface antigen loss or hepatitis B envelope antigen seroconversion did not occur. |
|---|